Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?
Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.
Kelun-Biotech’s ASCO 2026 data strengthens China’s next wave of targeted cancer drugs
Kelun-Biotech’s RET lung cancer data looks strong, but CNS durability and global competition will decide its real impact.
Can Thermo Fisher help Nuvation Bio scale Ibtrozi supply for ROS1-positive NSCLC?
Rare cancer drugs need more than FDA approval. Nuvation Bio’s Ibtrozi test now shifts to U.S. supply reliability and launch execution.
FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity
Rare cancer biology met regulatory urgency. Bizengri’s approval tests whether precision oncology can reach tiny patient subsets fast.
Why Partner Therapeutics’ BIZENGRI approval matters beyond cholangiocarcinoma
Rare cancer biology is becoming commercially actionable. BIZENGRI’s FDA approval puts NRG1 fusion testing under sharper scrutiny.
AbbVie Inc. secures strategic option on Kestrel Therapeutics Inc. amid KRAS innovation race
A new pan-KRAS approach enters Phase 1 backed by AbbVie Inc. Discover the implications for oncology pipelines and KRAS-driven cancers.
How Florida Cancer Specialists contributed to a study that may change KRAS G12D cancer treatment
Setidegrasib showed early activity in KRAS G12D lung and pancreatic cancers. Read why the Phase 1 signal could matter for oncology’s next target.
Dizal’s Zegfrovy challenges chemo dominance in rare EGFR lung cancer mutation
Zegfrovy Phase 3 results could redefine EGFR exon20ins lung cancer treatment. Discover what this means for frontline therapy and future care strategies.
Could IDEAYA Biosciences challenge current standards in metastatic uveal melanoma with darovasertib?
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
PAQ Therapeutics initiates Phase 1 for PT0511 pan-KRAS degrader, raises $77m in Series B
PAQ Therapeutics begins Phase 1 trial for PT0511 pan-KRAS degrader and raises $77M. Find out what this means for the future of KRAS-targeted cancer therapy.